Inclusion Criteria:~* Patients with diagnostics of Alzheimer's disease (AD) according to DSM-IV.~* Patients
with modified Hachinski Ischemic scale score of â‰¦6.~* FAST score of â‰§6 at baseline (4 weeks before starting
study treatment).~* MMSE score between 1 and 12 at baseline (4 weeks before starting study treatment).~*
Imaging diagnostics (CT, MRI, etc., within 24 months consistent with the diagnosis of AD without any other
comorbid pathologies found. If a significant change in clinical status suggesting other types of dementia
(except AD) is suspected between the final image diagnosis and the time of starting observation, the scan test
should be repeated.~* Patients who can comply with the requirements on concomitant drugs/therapies from the
baseline phase or before.~* Patients aged 50 years or older.~* Outpatients. Even in the case of an outpatient
or a patient attending on the outpatient-visit basis from a nursing home facility, the caregiver must be a
constant and reliable informant with minimum of 3 days per week direct contact with the patient (for at least 4
hours per day on waking hours). This contact is necessary to ensure accurate reporting of the patient's
behavior and his/her ability to perform ADLs.~* Patients who are expected to complete all procedures scheduled
during the Screening and Baseline visit and who have a reliable caregiver or family member who agrees to
accompany the patient to all clinic visits, provide information about the patient as required by the protocol,
and ensure compliance with the treatment schedule.~* Patients who can swallow tablets without pulverization.~*
Patients who are ambulatory at least aided (walker) and have vision and hearing necessary for compliance with
testing procedures (eyeglasses and/or hearing aid permissible).~* Patients whose representatives can sign the
written informed consent.~
